Consultation workshop | Preparedness for emerging diseases

Agenda

29.09.2016 • IMI Stakeholder Forum
Hotel Crowne Plaza Le Palace • Rue Gineste 3 • Brussels, Belgium

8:30 – 09:00 Registration & networking breakfast

09:00 – 9:30 Opening session
   Pierre Meulien, IMI Executive Director

9:30 Introduction to the consultation workshop
   Angela Wittelsberger, Scientific Officer, IMI

9:35 Setting the scene

09:35 – 9:50 Threats and risks at global level
   Marie-Paule Kieny, Assistant Director-General - Health Systems and Innovation, World Health Organization (WHO)

9:50 – 10:05 Current and Future Threats for Europe
   Piotr Kramarz, Deputy Chief Scientist, European Centre for Disease Prevention and Control (ECDC)

10:05 – 10:20 The European Commission: current research and innovation strategy and actions
   Line Matthiessen, Head of Unit, Fighting infectious diseases and advancing public health, DG Research & Innovation, European Commission

10:20 – 10:35 Coalition for Epidemic Preparedness Innovations (CEPI)
   John-Arne Røttingen, Director of the Division of Infectious Disease Control, Norwegian Institute of Public Health; CEPI

10:35 – 10:50 Questions & Answers

10:50 – 11:20 Coffee break

11:20 Key determinants of biopreparedness I: diagnostic platforms & early detection

11:20 – 11:30 The role of diagnostics in biopreparedness
   Mark Miller, Chief Medical Officer, BioMérieux

11:30 – 11:40 COMPARE - A global platform for the sequence-based rapid identification of pathogens
   Frank Møller Aarestrup, Professor, Head of Research Group, Technical University of Denmark; COMPARE project

11:40 – 12:30 Panel discussion on early detection and diagnostics
   Frank Møller Aarestrup, COMPARE project
   Marie-Paule Kieny, WHO
   Piotr Kramarz, ECDC
   Mark Miller, BioMérieux

Moderated by Evelyn Depoortere, European Commission
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:30 – 13:30</td>
<td>Lunch break</td>
</tr>
<tr>
<td>13:30 – 13:40</td>
<td>Key determinants of biopreparedness II: treatment and vaccine development</td>
</tr>
<tr>
<td>13:40 – 13:50</td>
<td>Perspectives on anti-infective therapeutic agents as part of a biopreparedness strategy</td>
</tr>
<tr>
<td>13:50 – 14:00</td>
<td>The industry perspective on vaccines: the way forward</td>
</tr>
<tr>
<td>14:00 – 14:45</td>
<td>Panel discussion: capacity and facilitating opportunities for vaccines and drug development</td>
</tr>
<tr>
<td>14:45 – 15:00</td>
<td>Coffee break</td>
</tr>
<tr>
<td>15:00 – 15:45</td>
<td>The legal and regulatory framework for licensure of medical countermeasures during public health emergencies</td>
</tr>
<tr>
<td>15:45 – 16:00</td>
<td>Discussion: How can public and private players help?</td>
</tr>
<tr>
<td>16:00 – 17:00</td>
<td>IMI Stakeholder Forum concluding remarks</td>
</tr>
</tbody>
</table>

**Exploration room**

13:30 – 13:40 Perspectives on anti-infective therapeutic agents as part of a biopreparedness strategy
- Kenny Simmen, Vice President, Innovation, Janssen Infectious Diseases & Vaccines

13:40 – 13:50 The industry perspective on vaccines: the way forward
- Jean Lang, Associate Vice President, R&D Policy Head, Sanofi Pasteur

13:50 – 14:00 EDCTP perspective on biopreparedness and related capacity development in Africa
- Michael Makanga, Executive Director, European & Developing Countries Clinical Trials Partnership (EDCTP)

14:00 – 14:45 Panel discussion: capacity and facilitating opportunities for vaccines and drug development
- Jean Christophe Audonnet, Senior Director, Research Strategy & Key Alliances EU-Asia, R&D External Innovation, Merial; ZAPI project
- Philippe Denoel, Director, External R&D, GlaxoSmithKline Biologicals
- Herman Goossens, Director of the Department of Clinical Pathology of the University Hospital, Professor of Microbiology at the University of Antwerp
- Michael Makanga, EDCTP
- Kenny Simmen, Janssen

Moderated by Jean Lang, Sanofi Pasteur

16:00 – 17:00 IMI Stakeholder Forum concluding remarks
- Feedback from rapporteurs of parallel sessions
- Conclusions by Maria Beatriz Da Silva Lima, Professor of Pharmacology and Pharmacotoxicology, Lisbon University, Chair of the IMI Scientific Committee